top of page
Depositphotos_349665294_S.jpg

The 3 Pillars

3 Challenging Cells to Innovate Cell and Gene Therapy

To broaden the target diseases, we aim to broaden the target cells.
Femtobiomed will ‘Scale-Out’ the transfection technology, to deliver new medicine to patients quicker.

The 3 Pillars
p301_sec01_img1.png

NK

Rare population

High expansion costs

Low viral transduction efficiency Compromised viability in transduction

p301_sec01_img3.png

MSC

Safety risks of viral transduction

Low LNP transfection efficiency

Poor engraftment

p301_sec01_img2.png

iPSC

Rare population

High expansion cost

Low reprogramming efficiency

Poor engraftment

Opportunities in Cell and Gene Therapy

Overcome industry challenges in the conventional viral CAGT sector with our proposed solutions

Challenge

 Femtobiomed’s

 Solutions 

자산 7_2x.png

High Price

CAR-T Therapy : 375,000 – 475,000 USD

Long Manufacturing
Process

Manufacturing 3 weeks, Shipping

> 1 week

Manufacturing
Failure Rate

22% - Out of specification issues

(Cell viability < 80%) 

14% - Manufacturing failure

(Inability to meet targeted dose)

Serious Side Effets

79% - Cytokine Release Syndrome
72% - Neuronal Toxicity

Unable to cure 
Solid Cancer

Absence of multiple target cell therapeutics
Difficulties of CAR-NK production

Reduced Price

CellShot enables nonviral delivery, reducing expensive raw materials

and manufacturing process costs 

< 1 Day Production

Manufactured within 10 mins per dose, within 1 Day including QC

High Cell Viability
& Production Yield

CellShot RTX reduces manufacturing failure rates and maximizes patient treatment potential by shortening production time

mRNA Transfection

Eliminating side effects through mRNA delivery and opening the possibilities of the multi-dosing cell therapeutics 

Multi-target
CAR-NK

Solid cancer treatment through mRNA-based multi-target CAR-NK with improved efficacy and production yield

Femtobiomed's Solutions

Proof of Concept

PoC Domains

Targeting cells and materials that go beyond the limits of existing technologies.

domains_2x.png
Proof of Concepts
Case 1
Case 1

Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine the viability and transfection efficiency after electroporation. The transfected PBMCs resulted a viability of 98.1% and an efficiency of 91.5%.

press to zoom
Case 2
Case 2

CAR-CD19 mRNA was transfected to Human Primary NK cells using CellShot® Partitioned Flow Transfection, which resulted in 97.1% CAR expression and 96.7% cell viability after electroporation.

press to zoom
Case 3
Case 3

CAR-CD19 mRNA was transfected to Human NK cell lines using CellShot® Partitioned Flow Transfection system, which resulted in 84.9% CAR expression and 94.0% cell viability after electroporation.

press to zoom
Case 4
Case 4

CAR-NK cells demonstrated highly potent and specific killing capabilities in vitro. CAR-NK exerted much higher cytotoxicity against the Nalm6 cells (P < 0.01 by two-tailed t-test for all comparisons at each Effector cell : Target cell ratio; E:T ratio.) than the non-transfected hNK cells (NT NK). To determine whether CAR-CD19-expressed hNK cells have cytotoxicity against Normal B cells expressing CD19, we performed tests using the GA-10 cell line as a target cell.

press to zoom
Case 5
Case 5

Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine viability and transfection efficiency after EP. The transfected NK cells resulted a viability of 94.3% and an efficiency of 99.4%.

press to zoom
Case 6
Case 6

Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine viability and transfection efficiency after EP. The transfected T cells resulted a viability of 95.6% and an efficiency of 94.8%.

press to zoom
Case 7
Case 7

Flow cytometric analysis of enhanced Green Fluorescent Protein (eGFP) mRNA was used to determine viability and transfection efficiency after EP. The transfected HepG2 cells resulted a viability of 99.0% and an efficiency of 92.2%.

press to zoom
case8
case8
press to zoom
case9
case9
press to zoom
bottom of page